Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis
Abstract Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multi...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2020-07, Vol.71 (2), p.415-418 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 418 |
|---|---|
| container_issue | 2 |
| container_start_page | 415 |
| container_title | Clinical infectious diseases |
| container_volume | 71 |
| creator | Seung, Kwonjune J Khan, Palwasha Franke, Molly F Ahmed, Saman Aiylchiev, Stalbek Alam, Manzur Putri, Fauziah Asnely Bastard, Mathieu Docteur, Wisny Gottlieb, Gary Hewison, Catherine Islam, Shirajul Khachatryan, Naira Kotrikadze, Tinatin Khan, Uzma Kumsa, Andargachew Lecca, Leonid Tassew, Yoseph Melaku Melikyan, Nara Naing, Ye Yint Oyewusi, Lawrence Rich, Michael Wanjala, Stephen Yedilbayev, Askar Huerga, Helena Mitnick, Carole D |
| description | Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Clinical Trials Registration. NCT02754765. |
| doi_str_mv | 10.1093/cid/ciz1084 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2311652216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciz1084</oup_id><sourcerecordid>2311652216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-d680cf510349ff2bdd9cbda07882a1642db58a028c0ddd13400d2b359527f4b63</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoO4uB968i45iSDtVpJOT_oos7oKuyjLeG7SSfVspDsZ87Gw_oL92WaY0aOHooqHh7fgJeQ1gw8MenFpnK3zm4Fqn5EzJsWq6WTPntcbpGpaJdQpOU_pJwBjCuQLcipYt-p6kGfkaV3mXCLSdfAPGJMLnupMO3obfL5P1Hn6XWeHPid6hwbdg_NbeoWzXrR3tjFV087v4R1u3YI-0SlEmu-RbiLqXEmmYaK39Y-zsWybiMmlrCvelBGjKXOo4CU5mfSc8NVxX5Afnz9t1l-am2_XX9cfbxojOOTGdgrMJBmItp8mPlrbm9FqWCnFNetabkepNHBlwFrLRAtg-ShkL_lqasdOXJB3h9xdDL8KpjwsLhmcZ-0xlDRwwVgnOWd79f1BNTGkFHEadtEtOj4ODIZ99UOtfjhWX-03x-AyLmj_uX-7rsLbgxDK7r9JfwAhPo9Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2311652216</pqid></control><display><type>article</type><title>Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Seung, Kwonjune J ; Khan, Palwasha ; Franke, Molly F ; Ahmed, Saman ; Aiylchiev, Stalbek ; Alam, Manzur ; Putri, Fauziah Asnely ; Bastard, Mathieu ; Docteur, Wisny ; Gottlieb, Gary ; Hewison, Catherine ; Islam, Shirajul ; Khachatryan, Naira ; Kotrikadze, Tinatin ; Khan, Uzma ; Kumsa, Andargachew ; Lecca, Leonid ; Tassew, Yoseph Melaku ; Melikyan, Nara ; Naing, Ye Yint ; Oyewusi, Lawrence ; Rich, Michael ; Wanjala, Stephen ; Yedilbayev, Askar ; Huerga, Helena ; Mitnick, Carole D</creator><creatorcontrib>Seung, Kwonjune J ; Khan, Palwasha ; Franke, Molly F ; Ahmed, Saman ; Aiylchiev, Stalbek ; Alam, Manzur ; Putri, Fauziah Asnely ; Bastard, Mathieu ; Docteur, Wisny ; Gottlieb, Gary ; Hewison, Catherine ; Islam, Shirajul ; Khachatryan, Naira ; Kotrikadze, Tinatin ; Khan, Uzma ; Kumsa, Andargachew ; Lecca, Leonid ; Tassew, Yoseph Melaku ; Melikyan, Nara ; Naing, Ye Yint ; Oyewusi, Lawrence ; Rich, Michael ; Wanjala, Stephen ; Yedilbayev, Askar ; Huerga, Helena ; Mitnick, Carole D</creatorcontrib><description>Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Clinical Trials Registration. NCT02754765.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciz1084</identifier><identifier>PMID: 31676905</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antitubercular Agents - therapeutic use ; Humans ; Mycobacterium tuberculosis ; Nitroimidazoles - therapeutic use ; Oxazoles - therapeutic use ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant - drug therapy</subject><ispartof>Clinical infectious diseases, 2020-07, Vol.71 (2), p.415-418</ispartof><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2019</rights><rights>The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-d680cf510349ff2bdd9cbda07882a1642db58a028c0ddd13400d2b359527f4b63</citedby><cites>FETCH-LOGICAL-c320t-d680cf510349ff2bdd9cbda07882a1642db58a028c0ddd13400d2b359527f4b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31676905$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seung, Kwonjune J</creatorcontrib><creatorcontrib>Khan, Palwasha</creatorcontrib><creatorcontrib>Franke, Molly F</creatorcontrib><creatorcontrib>Ahmed, Saman</creatorcontrib><creatorcontrib>Aiylchiev, Stalbek</creatorcontrib><creatorcontrib>Alam, Manzur</creatorcontrib><creatorcontrib>Putri, Fauziah Asnely</creatorcontrib><creatorcontrib>Bastard, Mathieu</creatorcontrib><creatorcontrib>Docteur, Wisny</creatorcontrib><creatorcontrib>Gottlieb, Gary</creatorcontrib><creatorcontrib>Hewison, Catherine</creatorcontrib><creatorcontrib>Islam, Shirajul</creatorcontrib><creatorcontrib>Khachatryan, Naira</creatorcontrib><creatorcontrib>Kotrikadze, Tinatin</creatorcontrib><creatorcontrib>Khan, Uzma</creatorcontrib><creatorcontrib>Kumsa, Andargachew</creatorcontrib><creatorcontrib>Lecca, Leonid</creatorcontrib><creatorcontrib>Tassew, Yoseph Melaku</creatorcontrib><creatorcontrib>Melikyan, Nara</creatorcontrib><creatorcontrib>Naing, Ye Yint</creatorcontrib><creatorcontrib>Oyewusi, Lawrence</creatorcontrib><creatorcontrib>Rich, Michael</creatorcontrib><creatorcontrib>Wanjala, Stephen</creatorcontrib><creatorcontrib>Yedilbayev, Askar</creatorcontrib><creatorcontrib>Huerga, Helena</creatorcontrib><creatorcontrib>Mitnick, Carole D</creatorcontrib><title>Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Clinical Trials Registration. NCT02754765.</description><subject>Antitubercular Agents - therapeutic use</subject><subject>Humans</subject><subject>Mycobacterium tuberculosis</subject><subject>Nitroimidazoles - therapeutic use</subject><subject>Oxazoles - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoO4uB968i45iSDtVpJOT_oos7oKuyjLeG7SSfVspDsZ87Gw_oL92WaY0aOHooqHh7fgJeQ1gw8MenFpnK3zm4Fqn5EzJsWq6WTPntcbpGpaJdQpOU_pJwBjCuQLcipYt-p6kGfkaV3mXCLSdfAPGJMLnupMO3obfL5P1Hn6XWeHPid6hwbdg_NbeoWzXrR3tjFV087v4R1u3YI-0SlEmu-RbiLqXEmmYaK39Y-zsWybiMmlrCvelBGjKXOo4CU5mfSc8NVxX5Afnz9t1l-am2_XX9cfbxojOOTGdgrMJBmItp8mPlrbm9FqWCnFNetabkepNHBlwFrLRAtg-ShkL_lqasdOXJB3h9xdDL8KpjwsLhmcZ-0xlDRwwVgnOWd79f1BNTGkFHEadtEtOj4ODIZ99UOtfjhWX-03x-AyLmj_uX-7rsLbgxDK7r9JfwAhPo9Z</recordid><startdate>20200711</startdate><enddate>20200711</enddate><creator>Seung, Kwonjune J</creator><creator>Khan, Palwasha</creator><creator>Franke, Molly F</creator><creator>Ahmed, Saman</creator><creator>Aiylchiev, Stalbek</creator><creator>Alam, Manzur</creator><creator>Putri, Fauziah Asnely</creator><creator>Bastard, Mathieu</creator><creator>Docteur, Wisny</creator><creator>Gottlieb, Gary</creator><creator>Hewison, Catherine</creator><creator>Islam, Shirajul</creator><creator>Khachatryan, Naira</creator><creator>Kotrikadze, Tinatin</creator><creator>Khan, Uzma</creator><creator>Kumsa, Andargachew</creator><creator>Lecca, Leonid</creator><creator>Tassew, Yoseph Melaku</creator><creator>Melikyan, Nara</creator><creator>Naing, Ye Yint</creator><creator>Oyewusi, Lawrence</creator><creator>Rich, Michael</creator><creator>Wanjala, Stephen</creator><creator>Yedilbayev, Askar</creator><creator>Huerga, Helena</creator><creator>Mitnick, Carole D</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200711</creationdate><title>Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis</title><author>Seung, Kwonjune J ; Khan, Palwasha ; Franke, Molly F ; Ahmed, Saman ; Aiylchiev, Stalbek ; Alam, Manzur ; Putri, Fauziah Asnely ; Bastard, Mathieu ; Docteur, Wisny ; Gottlieb, Gary ; Hewison, Catherine ; Islam, Shirajul ; Khachatryan, Naira ; Kotrikadze, Tinatin ; Khan, Uzma ; Kumsa, Andargachew ; Lecca, Leonid ; Tassew, Yoseph Melaku ; Melikyan, Nara ; Naing, Ye Yint ; Oyewusi, Lawrence ; Rich, Michael ; Wanjala, Stephen ; Yedilbayev, Askar ; Huerga, Helena ; Mitnick, Carole D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-d680cf510349ff2bdd9cbda07882a1642db58a028c0ddd13400d2b359527f4b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antitubercular Agents - therapeutic use</topic><topic>Humans</topic><topic>Mycobacterium tuberculosis</topic><topic>Nitroimidazoles - therapeutic use</topic><topic>Oxazoles - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seung, Kwonjune J</creatorcontrib><creatorcontrib>Khan, Palwasha</creatorcontrib><creatorcontrib>Franke, Molly F</creatorcontrib><creatorcontrib>Ahmed, Saman</creatorcontrib><creatorcontrib>Aiylchiev, Stalbek</creatorcontrib><creatorcontrib>Alam, Manzur</creatorcontrib><creatorcontrib>Putri, Fauziah Asnely</creatorcontrib><creatorcontrib>Bastard, Mathieu</creatorcontrib><creatorcontrib>Docteur, Wisny</creatorcontrib><creatorcontrib>Gottlieb, Gary</creatorcontrib><creatorcontrib>Hewison, Catherine</creatorcontrib><creatorcontrib>Islam, Shirajul</creatorcontrib><creatorcontrib>Khachatryan, Naira</creatorcontrib><creatorcontrib>Kotrikadze, Tinatin</creatorcontrib><creatorcontrib>Khan, Uzma</creatorcontrib><creatorcontrib>Kumsa, Andargachew</creatorcontrib><creatorcontrib>Lecca, Leonid</creatorcontrib><creatorcontrib>Tassew, Yoseph Melaku</creatorcontrib><creatorcontrib>Melikyan, Nara</creatorcontrib><creatorcontrib>Naing, Ye Yint</creatorcontrib><creatorcontrib>Oyewusi, Lawrence</creatorcontrib><creatorcontrib>Rich, Michael</creatorcontrib><creatorcontrib>Wanjala, Stephen</creatorcontrib><creatorcontrib>Yedilbayev, Askar</creatorcontrib><creatorcontrib>Huerga, Helena</creatorcontrib><creatorcontrib>Mitnick, Carole D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seung, Kwonjune J</au><au>Khan, Palwasha</au><au>Franke, Molly F</au><au>Ahmed, Saman</au><au>Aiylchiev, Stalbek</au><au>Alam, Manzur</au><au>Putri, Fauziah Asnely</au><au>Bastard, Mathieu</au><au>Docteur, Wisny</au><au>Gottlieb, Gary</au><au>Hewison, Catherine</au><au>Islam, Shirajul</au><au>Khachatryan, Naira</au><au>Kotrikadze, Tinatin</au><au>Khan, Uzma</au><au>Kumsa, Andargachew</au><au>Lecca, Leonid</au><au>Tassew, Yoseph Melaku</au><au>Melikyan, Nara</au><au>Naing, Ye Yint</au><au>Oyewusi, Lawrence</au><au>Rich, Michael</au><au>Wanjala, Stephen</au><au>Yedilbayev, Askar</au><au>Huerga, Helena</au><au>Mitnick, Carole D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2020-07-11</date><risdate>2020</risdate><volume>71</volume><issue>2</issue><spage>415</spage><epage>418</epage><pages>415-418</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Clinical Trials Registration. NCT02754765.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>31676905</pmid><doi>10.1093/cid/ciz1084</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2020-07, Vol.71 (2), p.415-418 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2311652216 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Antitubercular Agents - therapeutic use Humans Mycobacterium tuberculosis Nitroimidazoles - therapeutic use Oxazoles - therapeutic use Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy |
| title | Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A16%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Culture%20Conversion%20at%206%20Months%20in%20Patients%20Receiving%20Delamanid-containing%20Regimens%20for%20the%20Treatment%20of%20Multidrug-resistant%20Tuberculosis&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Seung,%20Kwonjune%20J&rft.date=2020-07-11&rft.volume=71&rft.issue=2&rft.spage=415&rft.epage=418&rft.pages=415-418&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciz1084&rft_dat=%3Cproquest_cross%3E2311652216%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2311652216&rft_id=info:pmid/31676905&rft_oup_id=10.1093/cid/ciz1084&rfr_iscdi=true |